๐๐ฟ๐ผ๐บ ๐๐ฝ๐ฟ๐ฒ๐ฎ๐ฑ๐๐ต๐ฒ๐ฒ๐๐ ๐๐ผ ๐๐: ๐ต๐ผ๐ ๐ฅ๐ถ๐๐ถ๐ฎ ๐ถ๐ ๐ฟ๐ฒ๐ฏ๐๐ถ๐น๐ฑ๐ถ๐ป๐ด ๐๐ต๐ฒ ๐ฏ๐ฎ๐ฐ๐ธ๐ฏ๐ผ๐ป๐ฒ ๐ผ๐ณ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐ถ๐ฎ๐น๐
Clinical trials are one of the most data-intensive processes in medicine โ and one of the least technologically advanced. Biotech and pharma teams still spend thousands of hours manually validating, reconciling, and monitoring trial data across fragmented spreadsheets and legacy systems. The result: slower trials, higher costs, and ultimately delayed access to treatments for patients who have no other options.
Rivia was founded to fix this. The Zurich-based company built an AI platform that takes over the full data operations layer of a clinical trial โ integrating heterogeneous data sources in real time, automating quality control and monitoring, and making trial data instantly queryable for clinical teams. What previously required weeks of manual work can now be done in days, with the platform learning and improving across every trial it runs.
Rivia has now closed a $15 million Series A financing round to accelerate this next phase. The round was led by Earlybird Venture Capital, with additional participation from Defiant and existing investors Speedinvest, Amino Collective, and Nina Capital.
The new funds will enable Rivia to ๐ฒ๐
๐ฝ๐ฎ๐ป๐ฑ ๐ถ๐๐ ๐ฝ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ ๐ฐ๐ฎ๐ฝ๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ถ๐ฒ๐, ๐ฎ๐ฐ๐ฐ๐ฒ๐น๐ฒ๐ฟ๐ฎ๐๐ฒ ๐ถ๐ป๐๐ฒ๐ฟ๐ป๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ด๐ฟ๐ผ๐๐๐ต, ๐ฎ๐ป๐ฑ ๐ณ๐๐ฟ๐๐ต๐ฒ๐ฟ ๐ฒ๐๐๐ฎ๐ฏ๐น๐ถ๐๐ต ๐ถ๐๐ ๐ฝ๐ผ๐๐ถ๐๐ถ๐ผ๐ป ๐ฎ๐ ๐ฎ ๐น๐ฒ๐ฎ๐ฑ๐ฒ๐ฟ ๐ถ๐ป ๐ฎ๐ด๐ฒ๐ป๐๐ถ๐ฐ ๐๐-๐ฑ๐ฟ๐ถ๐๐ฒ๐ป ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐ถ๐ฎ๐น ๐๐ผ๐น๐๐๐ถ๐ผ๐ป๐. By pioneering advanced AI technology, Rivia is transforming clinical trials into faster, more cost-efficient processes to improve patient care and reduce time-to-market for life-saving treatments.
Kellerhals Carrard advised Rivia on all legal aspects of this transaction. The Kellerhals Carrard team was comprised of:
Karim Maizar (Partner, Corporate/VC)
Norbert Schenk (Senior Associate, Corporate/VC)
Simon Gluch (Associate, Corporate/VC)
Melissa Wiss (Paralegal, Corporate/VC)
Erik Scalfaro, CEO and co-founder of Rivia, ๐ฟ๐ฒ๐ณ๐น๐ฒ๐ฐ๐๐ฒ๐ฑ ๐ผ๐ป ๐๐ต๐ฒ ๐ฐ๐ผ๐น๐น๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ถ๐ผ๐ป: โKellerhals Carrard was instrumental in closing our Series A. Their technical rigour, precision, and commercial pragmatism made them a highly reliable partner for navigating our transaction at speed.โ
Congratulations to Erik Scalfaro and Tiago Kieliger. This milestone reflects their early conviction to build the hard infrastructure first โ and the results it is now delivering for clinical teams, investors, and ultimately the patients waiting on the other side of these trials.
